MannKind Corporation (NASDAQ:MNKD)’s shares gained 3.42% to $9.84. The company will present at upcoming conferences: Goldman Sachs 35th Annual Global Healthcare Conference on June 12, 2014 at 11:20 am (PT) at the Terranea Resortin Rancho Palos Verdes, California. MannKind Corporation (NASDAQ:MNKD), weekly performance is 29.01%. On last trading day company shares ended up $10.54. Analysts mean target price for the company is $8.58. MannKind Corporation (NASDAQ:MNKD), distance from 50-day simple moving average (SMA50) is 57.99%.
Ophthotech Corp (NASDAQ:OPHT), CFO Bruce Peacock unloaded 13,931 shares of the stock on the open market in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $40.12, for a total transaction of $558,911.72. Ophthotech Corp (NASDAQ:OPHT), advanced 3.83% in last trading session and ended the day on $43.35. NI, return on assets is -45.70%. Ophthotech Corp (NASDAQ:OPHT), quarterly performance is 11.33%.
Repligen Corporation (NASDAQ:RGEN), announced recently that it has acquired the business of Refine Technology (“Refine”), including Refine’s Alternating Tangential Flow (“ATF”) System, a market-leading device used to significantly increase product yield during the fermentation step of the biologic drug manufacturing process. The acquisition strengthens Repligen’s bioprocessing business by adding a profitable and highly complementary product line while expanding the Company’s direct sales presence worldwide. Repligen Corporation (NASDAQ:RGEN), shares moved up 6.89% in last trading session and was closed at $20.48, while trading in range of $19.01 – 21.13. Repligen Corporation (NASDAQ:RGEN), year to date (YTD) performance is 50.15%.
Investment analysts at Wells Fargo & Co. started coverage on shares of Alder Biopharmaceuticals Inc (NASDAQ:ALDR), in a note issued to investors on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating on the stock. Alder Biopharmaceuticals Inc (NASDAQ:ALDR), ended the last trading day at $13.92. Company weekly volatility is calculated as 8.12% and price to cash ratio as 17.95. Alder Biopharmaceuticals Inc (NASDAQ:ALDR), showed a positive weekly performance of 33.46%.
Jefferies Group assumed coverage on shares of China Biologic Products Inc (NASDAQ:CBPO), in a report released on Thursday, TheFlyOnTheWall.com reports. The firm issued a buy rating and a $52.00 price objective on the stock. China Biologic Products Inc (NASDAQ:CBPO), net profit margin is 33.90% and weekly performance is 1.50%. On last trading day company shares ended up $43.93. Analysts mean target price for the company is $51.00. China Biologic Products Inc (NASDAQ:CBPO), distance from 50-day simple moving average (SMA50) is 19.51%.
Leave a Reply